DUBLIN–(BUSINESS WIRE)–The report “Global Central Nervous System Partnering 2015-2022: Deal Trends, Players and Financials” has been added to from ResearchAndMarkets.com offer.
The Global Central Nervous System Partnering 2015-2022 report provides comprehensive access to agreements and contract documents available for over 1,700 central nervous system agreements.
Most transactions included in the report occur when a licensee obtains a right or option to license the product or technology from a licensor. More often than not these days, these agreements tend to be multi-component, including both collaborative R&D and an element of commercializing the results.
The report guides readers through comprehensive Central Nervous System Disease Agreement trends, key players, and major agreement values to understand how, why, and under what conditions companies are currently entering into Central Nervous System Agreements .
The report presents the values of financial transaction terms for Central Nervous System transactions, where applicable, a listing by global global values, upfront payments, milestones and royalties allowing readers to analyze and compare the value of ongoing transactions .
Chapter 1 provides an introduction to the report.
Chapter 2 provides an overview of trends in central nervous system transactions since 2015, covering trends by year, type of transaction, stage of development, type of technology and therapeutic indication.
Chapter 3 includes an analysis of the terms of the financial agreement covering aggregate value, upfront payment, milestone payments and royalty rates.
Chapter 4 reviews the top central nervous system deals since 2015. The deals are listed by global value. The chapter includes the top 25 most active central nervous system negotiators, along with a comprehensive list of the agreements to which they are party. When the agreement has an agreement contract published to the SEC, a link provides online access to the contract.
Chapter 5 provides full access to central nervous system offerings since 2015 when an agreement contract is available, providing the user with direct access to contracts filed with SEC regulators. Each transaction title is linked via Weblink to an online version of the transaction record contract document, providing easy access to each contract document upon request.
Chapter 6 provides a comprehensive directory of all central nervous system partnership offerings by specific central nervous system target announced since 2015. The chapter is organized by specific central nervous system therapeutic target. Each transaction title is linked via Weblink to an online version of the transaction record and, where applicable, the contract document, providing easy access to each contract document upon request.
In addition, a comprehensive appendix is provided with each report of all partnership agreements signed and announced since 2015. The appendices are organized by AZ company, stage of development at signing, type of agreement (collaborative R&D, co-promotion, license, etc.) and type of technology. Each transaction title is linked via Weblink to an online version of the transaction record and, where applicable, the contract document, providing easy access to each contract document upon request.
The report includes offers for the following indications: cerebral palsy, Creutzfeldt-Jakob disease, dizziness, epilepsy, fainting, falls, Guillain Barre syndrome, headache, meningitis (bacterial, meningococcal, pneumococcal), Mycobacterium tuberculosis (TB), Haemophilus influenzae type B (Hib), migraine, motor neurone disease (amyotrophic lateral sclerosis/Lou Gehrig’s disease, multiple sclerosis, nausea, neuropathy, pain, neuralgia, fibromyalgia, paralysis, Parkinson’s disease, restless legs syndrome, spinal cord, stroke, stuttering, head trauma, vertigo, weakness, as well as other CNS indications.
The Global Central Nervous System Partnership 2015-2022 includes:
Trends in central nervous system transactions in the biopharmaceutical industry since 2015
Analysis of the structure of transactions of the central nervous system
Access to master, initial, milestone and royalty data
Access to hundreds of central nervous system contract documents
Full access to over 1,700 central nervous system transaction records
Top central nervous system transactions by value since 2015
Most active central nervous system negotiators since 2015
In Global Central Nervous System Partnering 2015 to 2022, available offers and contracts are listed by:
Initial Payment Value
Royalty rate value
Stage of development at signing
Offer component type
Type of technology
Specific therapeutic indication
The analysis of the actual contractual agreements makes it possible to evaluate the following elements:
What specific rights are granted or optional?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the transaction?
How are sales and payments audited?
What is the duration of the agreement?
How are the main terms of the agreement defined?
How are IPRs managed and owned?
Who is responsible for marketing?
Who is responsible for development, supply and manufacturing?
How are confidentiality and publication managed?
How to settle disputes?
Under what conditions can the agreement be terminated?
What happens if the owner changes?
What sub-licensing and sub-contracting arrangements have been agreed upon?
What boilerplate clauses does the company insist on?
What boilerplate clauses seem to differ from one partner to another or from one type of transaction to another?
What jurisdiction does the company insist on for contract law?
Main topics covered:
Chapter 1 Introduction
Chapter 2 – Trends in Central Nervous System Negotiations
2.2. Central nervous system partnership over the years
2.3. Central Nervous System Partnerships by Transaction Type
2.4. Central Nervous System Partnerships by Industry Sector
2.5. Central nervous system partnership by developmental stage
2.6. Central nervous system partnerships by type of technology
2.7. Partnership of the Central Nervous System by therapeutic indication
Chapter 3 – Terms of Financial Agreement for Central Nervous System Partnership
3.2. Financial Terms Disclosed for Central Nervous System Partnership
3.3. Central Nervous System Partnership Core Values
3.4. The central nervous system processes the initial payments
3.5. Central Nervous System Agreement Milestone Payments
3.6. Central nervous system royalty rate
Chapter 4 – Major Central Nervous System Agreements and Negotiators
4.2. Most active in central nervous system partnership
4.3. List of most active negotiators in the central nervous system
4.4. Top Central Nervous System Deals by Value
Chapter 5 – Central Nervous System Contract Documents Directory
5.2. Central nervous system partnership agreements when a contract document is available
Chapter 6 – Central Nervous System transactions by therapeutic target
6.2. Offerings by Central Nervous System Therapeutic Target
Annex 1 – Directory of central nervous system offers by AZ company 2015 to 2022
Appendix 2 – Directory of central nervous system transactions by type of transaction from 2015 to 2022
Appendix 3 – Directory of central nervous system transactions by stage of development 2015 to 2022
Annex 4 – Directory of central nervous system transactions by type of technology from 2015 to 2022
For more information about this report visit https://www.researchandmarkets.com/r/tiuyvc